GlassScriptPhysician profile
Michael M Strauss
NPI 1962781781
$3,746.27
in general payments reported to CMS, 2019-2025
19 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $297 · 2021: $304 · 2022: $777 · 2023: $789 · 2024: $673 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800 · Education: $77.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.77 |
| Education | $77.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $787.76 | 2019-2023 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $512.50 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $402.64 | 2022-2025 | |
| Glaxosmithkline, LLC. | $284.06 | 2022-2023 | Jesduvroq, Benlysta |
| Horizon Therapeutics Plc | $269.59 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $197.90 | 2023 | Tarpeyo |
| Akebia Therapeutics INC | $161.45 | 2019-2024 | Auryxia, Vafseo |
| Ardelyx, INC. | $149.10 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $142.69 | 2024 | Terlivaz |
| Novo Nordisk INC | $138.23 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $137.21 | 2024-2025 | Jardiance |
| Ossio INC | $131.32 | 2023 | |
| Baxter Healthcare | $116.88 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $106.58 | 2020 | |
| Amgen INC. | $99.01 | 2023-2024 | Tavneos, Krystexxa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $44.93 | 2024 | Lupkynis |
| Janssen Pharmaceuticals, INC | $23.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.90 | 2023 | Jardiance |
| Esperion Therapeutics, INC. | $19.09 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.